Medicare covers several GLP-1 medications, but only when they’re prescribed for type 2 diabetes or, in one specific case, cardiovascular risk reduction. Federal law prohibits Medicare from covering any drug used solely for weight loss, which means the reason your doctor prescribes a GLP-1 determines whether Medicare will pay for it.
GLP-1 Drugs Covered Under Part D for Diabetes
Medicare Part D plans can cover GLP-1 receptor agonists when they’re prescribed to treat type 2 diabetes. The specific drugs available to you depend on your plan’s formulary (its list of covered medications), but the GLP-1s most commonly included are Ozempic (semaglutide injection), Rybelsus (semaglutide taken as a pill), Mounjaro (tirzepatide), and Trulicity (dulaglutide). Older GLP-1s like Victoza (liraglutide) and Byetta (exenatide) may also appear on some formularies.
Each Part D plan negotiates its own drug list, so coverage varies. One plan might place Ozempic on a preferred tier with lower copays while another might favor Trulicity. Some plans may not cover certain GLP-1s at all or may require you to try a less expensive diabetes medication first. Checking your specific plan’s formulary is the only way to know exactly which GLP-1 is covered and what you’ll pay.
The Weight Loss Exclusion
Section 1860D-2(e)(2) of the Social Security Act explicitly excludes “agents when used for anorexia, weight loss, or weight gain” from Part D coverage. This is a statutory ban, not a policy choice by individual plans. No Part D plan, whether standalone or through Medicare Advantage, can cover a GLP-1 if the sole purpose is weight management.
This exclusion is why Zepbound (tirzepatide), which is FDA-approved specifically for weight loss and obstructive sleep apnea, is not covered by Medicare. Even though Zepbound contains the same active ingredient as Mounjaro, its approved uses fall outside what Medicare can pay for. Wegovy (semaglutide), the weight loss version of Ozempic, faces the same barrier when prescribed purely for obesity.
Wegovy’s Cardiovascular Exception
There is one important nuance. The FDA approved Wegovy for a second use: reducing the risk of heart attack, stroke, and cardiovascular death in adults who already have cardiovascular disease and are either obese or overweight. That approval was based on a trial of more than 17,600 participants showing meaningful reductions in serious heart events.
This cardiovascular indication is distinct from weight loss, which opens a potential pathway for Medicare coverage. When Wegovy is prescribed specifically to reduce cardiovascular risk rather than for weight management, it may qualify for Part D coverage depending on your plan. The distinction matters: your doctor’s documentation needs to clearly reflect the cardiovascular purpose of the prescription.
Prior Authorization and Step Therapy
Even when a GLP-1 is on your plan’s formulary, expect additional hurdles before coverage kicks in. Most Part D plans and Medicare Advantage plans require prior authorization for GLP-1 drugs. Major insurers like Blue Cross Blue Shield and UnitedHealthCare have implemented prior authorization specifically to confirm that the prescription is for a type 2 diabetes diagnosis, not weight loss.
Your plan may also require step therapy, meaning you’ll need to show that you tried one or more less expensive diabetes medications (typically metformin) before the plan will approve a GLP-1. This process involves your doctor submitting clinical documentation to the insurer. If your prior authorization is denied, you have the right to appeal. The timeline for approval can range from a few days to a couple of weeks, so it helps to start the process early.
What You’ll Pay Out of Pocket
GLP-1 medications are expensive, with list prices often exceeding $1,000 per month. But a major change took effect in 2025 that limits your financial exposure. Under the Inflation Reduction Act, Medicare Part D beneficiaries now pay no more than $2,000 total out of pocket per year for all covered prescriptions. Once you hit that cap, you owe nothing more for the rest of the year.
For someone taking a high-cost GLP-1, this means you might reach the $2,000 cap within just a few months, after which your remaining refills for the year are fully covered. There’s also a new Medicare Prescription Payment Plan that lets you spread your out-of-pocket costs across the year in smaller monthly payments rather than paying large sums upfront. This is available to anyone with a Part D plan, whether standalone or through Medicare Advantage.
One important limitation: manufacturer savings cards and copay programs for GLP-1 drugs, like those offered by Eli Lilly for Zepbound, are not available to people on Medicare. You cannot combine these commercial discount programs with government insurance.
Medicare Advantage vs. Original Medicare
Medicare Advantage plans must offer at least the same drug coverage as Original Medicare’s Part D, but they cannot override the federal weight loss exclusion. Some people assume that because Medicare Advantage plans can offer supplemental benefits (like dental or vision), they might also cover weight loss medications. They cannot. The statutory ban applies equally to all forms of Medicare.
Where Medicare Advantage plans can differ is in which specific GLP-1s they place on their formularies for diabetes and what tier they assign them to. If your current plan doesn’t cover the GLP-1 your doctor recommends, switching plans during open enrollment may give you better options. Comparing formularies across plans before enrolling is worth the effort, especially if you know you’ll need a specific medication.
Compounded GLP-1 Medications
During drug shortages, compounding pharmacies have produced custom versions of semaglutide and tirzepatide at lower prices. These compounded versions are not the same as FDA-approved brand-name drugs, and Medicare Part D plans generally do not cover them. Compounded medications occupy a gray area in Medicare’s coverage rules, and most plans exclude them from their formularies entirely. If you’re considering a compounded GLP-1, expect to pay out of pocket.